Marksans Pharma Limited will participate in a virtual investor conference organized by Choice Institutional Equities on June 10, 2026, at 03:00 PM IST. Company officials are scheduled to attend the session to engage with investors. The company confirmed that no unpublished price sensitive information (UPSI) will be discussed during the conference.

The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to BSE Limited and the National Stock Exchange of India Limited.

Marksans Pharma reported a 9.8% year-on-year increase in consolidated net profit to ₹420.1 crore for the financial year ended March 31, 2026. Revenue from operations rose 12.5% to ₹2,950.9 crore from ₹2,622.8 crore in the previous year. The company achieved its highest-ever total income of approximately ₹3,033 crore, with EBITDA reaching ₹600.8 crore and a margin of 20.4%, surpassing its guidance range of 16–18%. The company filed an investor presentation for Q4FY26 with the exchanges on May 26, 2026, detailing these results.

Key Financial Highlights

The following table summarizes Marksans Pharma's consolidated financial performance for the year ended March 31, 2026:

Operational Performance and Margins

For the quarter ended March 31, 2026, the company reported consolidated revenue of ₹856.1 crore, a 20.8% increase from ₹708.5 crore in the corresponding quarter of the previous year. The consolidated net profit for Q4 FY26 stood at ₹149 crore, compared to ₹90.7 crore in Q4 FY25. The EBITDA for the quarter improved to ₹195.4 crore from ₹126.9 crore in the prior year, reflecting enhanced operational efficiency and cost management. The gross margin for the quarter was 54.4%, while the EBITDA margin stood at 22.8%.

Strategic Developments

During the year, Marksans Pharma incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. Additionally, the company implemented the Marksans Employees Stock Option Scheme 2024, granting 400,000 equity stock options to eligible employees. The financial statements were audited by M/s. MSKA & Associates LLP, Statutory Auditors, who issued an unmodified opinion. The Board of Directors has also recommended a final dividend of ₹0.90 per equity share for the financial year 2025-26, subject to shareholder approval.

Management Commentary

Management stated that FY26 was a milestone year, with the company delivering on its guidance and achieving the highest-ever total income of approximately ₹3,033 crore. EBITDA reached ₹600.8 crore with a margin of 20.4%, surpassing the guided range of 16–18%, and PAT hit an all-time high of ₹420.1 crore. Growth was led by new launches across markets, including the Rx branded portfolio in Australia, and a strong recovery in the UK during Q4. The company closed the year with a cash balance of approximately ₹990 crore, maintaining a net cash positive position for over five consecutive years.

During an investor call held on May 27, 2026, management provided guidance for FY27, targeting revenue growth between 15% and 20% while maintaining EBITDA margins around 20%. The company remains optimistic about achieving its ₹4,000 crore revenue target by FY28. Management noted that while raw material costs have risen by 20% to 30% due to geopolitical factors, the impact is mitigated by existing inventory and favorable foreign exchange movements. The Teva facility utilization is close to 50%, with potential for further growth. The company is actively evaluating acquisition targets and expects M&A activity in 2027.